

Muzinich & Co. supports Direct Healthcare Group with a new financing package

London [●] June 2020.

Muzinich & Co. announced today it has provided a new unitranche financing package to support Direct Healthcare Group (“DHG”), a portfolio company of ArchiMed - a pan-European investment firm specialising in the healthcare industry. Archimed acquired DHG in December 2019.

DHG is a fully integrated developer and manufacturer of a range of innovative pressure care products designed to prevent medical issues such as pressure sores, which can lead to serious diseases. Founded in 2009, the business works with care providers in over 20 countries throughout Europe and internationally.

In May 2020, DHG acquired the Patient Handling Europe division of Swedish-listed group Handicare Group AB - the division is a specialist provider of transfer solutions that simplify mobility for patients in hospitals, acute care environments, group homes and private homes. The acquisition deepened DHG’s range of products and widened its geographical reach, putting it on course to be the leading pan-European provider of products and solutions for the care of patients with limited mobility.

“We are very pleased to be supporting ArchiMed and the first-rate DHG management team as they continue on their strategy of becoming the pan-European leader in the mobility-related medical devices and services markets” says John Clifford, UK co-head of the Muzinich & Co. private debt platform.

Muzinich & Co. has recently also completed a further two new deals, providing a unitranche financing package to support Caption’s acquisition of Healthfood 24 in Germany and financing to support Söderberg & Partners’ investment in APC Forsikringsmæglere A/S (“APC”).

Based in Leipzig, Germany, Healthfood 24 is a leading provider of high-quality premium gluten free pet food for domestic dogs and cats through its two brands Wolfsblut and Wildcat.

APC is the largest B2C pension broker in Denmark and one of the leading fintech developers in the industry, a position that Söderberg & Partners hopes to help APC further strengthen through cooperation around fintech development capabilities.

Click [here](#) for a full list of investments made in Muzinich’s private debt platform.

ENDS

For further information, contact:

Naeem Taidi, Muzinich & Co

+44 (0) 203 693 8755

ntaidi@muzinich.com

About ArchiMed

ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors. ArchiMed's international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth through internationalization, product and service range expansion and capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed's leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above five billion euros. ArchiMed's investment capacity currently exceeds one billion euros and is potentially twice this amount when including its strategic investment partners.

About Muzinich & Co

"Muzinich & Co.", "Muzinich", and/or the "Firm" referenced herein is defined as Muzinich & Co., Inc. and its affiliates (including but not limited to Muzinich & Co. Limited and Muzinich BDC Adviser, LLC.) Muzinich & Co. is a privately owned, institutionally focused investment firm specializing in public and private corporate credit. The firm was founded in New York in 1988 and has offices in London, Frankfurt, Madrid, Manchester, Milan, Paris, Singapore, Zurich and Dublin. Muzinich offers a broad range of corporate credit funds across both developed and emerging markets.

This document and the views and opinions expressed herein are provided for informational purposes only and do not constitute any advice or recommendation, to purchase or sell any securities or other financial instruments and may not be construed as such. It should not be assumed that an investment in the loan identified and discussed was or will be profitable. All information contained herein is believed to be accurate as of the date(s) indicated, is not complete, and is subject to change at any time.

Issued by Muzinich & Co. Limited, which is authorized and regulated by the Financial Conduct Authority. Registered in England and Wales No. 3852444. Registered address: 8 Hanover Street, London W1S 1YQ. Muzinich & Co. Limited. is a subsidiary of Muzinich & Co., Inc. Muzinich & Co., Inc. and its affiliate Muzinich BDC Adviser, LLC are Registered Investment Advisers with the Securities and Exchange Commission (SEC). Being a Registered Investment Adviser with the SEC in no way shall imply a certain level of skill or training or any authorization or approval by the SEC.